The senior unsecured term loan facility was used, in part, to refinance a three-year loan agreement between BD, Citibank, and other lenders reached last year.
The investment bank said that it thinks 2018 will be a good year for clinical sequencing and that overall demand for high-throughput sequencing remains high.
Wells Fargo downgraded Cepheid from Outperform to Market Perform, citing the firm's "credibility and visibility" following a revised 2017 outlook.
In a report issued today, analysts said the company failed to provide "meaningfully improved visibility on broader reimbursement and revenue progression."
The investment bank noted stabilization in Myriad's BRCA1/2 testing franchise, the firm's new management, and its new products.
The upgrade follows four consecutive quarters of above-industry-average revenue growth, driven by the biopharma end market, and the addition of a new CEO.
The Associated Press reports that gene-edited food may soon be for sale.
The United Nations is to consider a ban on field testing gene drives at a meeting being held next week, Technology Review reports.
The US Department of Health and Human Services is beginning a series of meetings on human fetal tissue research, Stat News reports.
In Cell this week: epigenetic change linked to glioblastomas, rare and low-frequency variants contributing to multiple sclerosis risk, and more.